|
Synonyms: ALTUVIIIO® | BIVV-001 | BIVV001 | Fc-VWF-XTEN
efanesoctocog alfa is an approved drug (FDA (2023))
Compound class:
Peptide or derivative
Comment: Efanesoctocog alfa (BIVV-001) is a recombinant protein that fuses factor VIII (FVIII) to a human IgG1 Fc domain. It was designed as a long-acting FVIII replacement therapy [4]. Pharmacodynamic effects of efanesoctocog alfa (clot formation) are identical to those elicited by recombinant FVIII [1].
|
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (FDA (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11314 | efanesoctocog alfa |
| Synonyms |
| ALTUVIIIO® | BIVV-001 | BIVV001 | Fc-VWF-XTEN |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 701 |
| Other databases | |
| GtoPdb PubChem SID | 491299868 |
| Search PubMed clinical trials | efanesoctocog alfa |
| Search PubMed titles | efanesoctocog alfa |
| Search PubMed titles/abstracts | efanesoctocog alfa |
